Document Detail


Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature.
MedLine Citation:
PMID:  21618056     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Neuroendocrine tumors (NET) are rare, but their incidence is gradually increasing. In this study, demographical and tumor characteristics, treatment modalities, responses, and survival rates were evaluated in the patients with NET. Seventy-one patients with NET from 3 tertiary care centers evaluated retrospectively. Overall survival (OS), progression-free survival (PFS), and disease-free survival rates were estimated by Kaplan-Meier Method. Male/female ratio was 0.86 (33/38). Median age was 52 years. Rates for family cancer history and goiter/thyroiditis were 22.4 and 17.8%, respectively. The most common primary site was lung (22.5%), in parallel with the literature, and 31% had the large cell neuroendocrine carcinoma histology. The second most common site was stomach. Carcinoid syndrome rate was found to be 30.6%. Half of the patients were in early stage at diagnosis. Surgical resection rate was 64.7, and 45% of the patient received chemotherapy (CT), 22% received radiotherapy. Seventy-six percent of resected patients had local disease. Thirty-two patients received CT for palliation or concurrent with radiotherapy or in adjuvant setting. Platin/etoposide combination was the most commonly used chemotherapy regimen. Chemotherapy response rate was 35.7%. Five patients had received somatostatin analogue. Radiotherapy was used in adjuvant setting in one-third of the patients. Median OS was 66 months, and median PFS was 30 months. Female gender and fifth decade seem to have higher risk. History for family cancer and goiter/thyroiditis was high in the patients with NET, though there is no data about an association between NET and thyroid disorders in the literature.
Authors:
Mutlu Dogan; Bulent Yalcin; Nuriye Yildirim Ozdemir; Ulku Yalcintas Arslan; Lutfi Dogan; Gungor Utkan; Hakan Akbulut; Nurullah Zengin; Necati Alkis; Fikri Icli
Related Documents :
23485996 - Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothe...
23523056 - Mtor inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
20102116 - Health-related quality of life aspects in patients with low-grade glioma.
12576426 - Predictive value of the epha2 receptor tyrosine kinase in lung cancer recurrence and su...
22231626 - Clinical significance and prognostic value of pax3 expression in human glioma.
6754066 - Current management of advanced and locally unresectable gastric carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-27
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  -     ISSN:  1559-131X     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Medical Oncology, Ankara University School of Medicine, Cebeci Hospital, 06590, Dikimevi, Ankara, Turkey, mutludogan1@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimizing bioimpedance measurement configuration for dual-gated nuclear medicine imaging: a sensiti...
Next Document:  Acute transient encephalopathy after weekly paclitaxel infusion.